Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (January 2013)
19 slides from Paratek Pharmaceuticals's investor presentation, Jan 7, 2013
Slide 1: January 2013
January 2013 January 2013 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Examples of such statements include our expectations regarding the potentia
Slide 3: Transcept corporate overview
Dec 31 2012: ~$ 85 M cash & equivalents, net of $10M Intermezzo DTC investment Neuroscience / psychiatry First and only Rx sleep aid approved for middle-of- the-night dosing U.S. primary care partnership: Purdue Pharma $29M 6-month DTC campaign: TV launch Jan 2013 600+ Purdue sales reps presenting I
Slide 4: Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing Indication statement as approved by FDA: – Intermezzo is indicated for use as needed for the treatment of insomn
Slide 5: Intermezzo unit dose bedside packaging
Intermezzo unit dose bedside packaging Intermezzo unit dose bedside packaging “Intermezzo is to be taken in bed when a patient wakes in the middle of the night and has difficulty returning to sleep. Intermezzo should only be taken if the patient has at least 4 hours of bedtime remaining before the p
Slide 6: Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category
Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category Middle of the night (MOTN) awakening: a major unmet medical need in the insomnia category Large U.S. insomnia market – million new and refill prescriptions (1) Insomnia is an under-treated condition (2) – milli
Slide 7: Commonly prescribed sleep aids are indicated only for bedtime use
Commonly prescribed sleep aids are indicated only for bedtime use Commonly prescribed sleep aids are indicated only for bedtime use MOTN awakenings typically do not occur every night 7-8 hr sleep aids (Ambien ® , Ambien CR ® , Lunesta ® ) require bedtime prophylactic dosing to prevent awakenings An
Slide 8: Intermezzo: the first and only sleep aid approved for middle-of-the night dosing
Intermezzo: the first and only sleep aid approved for middle-of-the night dosing Intermezzo: the first and only sleep aid approved for middle-of-the night dosing Novel zolpidem formulation – Sublingual tablet – Bicarbonate-carbonate buffers Approved dose – 1.75 mg in women & patients > 65 years – 3.
Slide 9: Purdue commercialization agreement: key Transcept benefits
Purdue commercialization agreement: key Transcept benefits Purdue commercialization agreement: key Transcept benefits Base royalty: mid-teens up to mid 20% level on net sales Milestone payments – Received: $25M up front + $20M for IP-related milestones – Potential: Up to an additional $70M related t
Slide 10: Intermezzo weekly TRx post-launch
Week post-launch Intermezzo Thanksgiving holiday week Intermezzo weekly TRx as of 12/21/12
Slide 11: Purdue DTC campaign launch January 2013
Purdue DTC campaign launch January 2013 Purdue DTC campaign launch January 2013
Slide 12: Intermezzo ad placement on leading TV networks
Intermezzo ad placement on leading TV networks Intermezzo ad placement on leading TV networks
Slide 13: DTC launch and broadened Intermezzo commercialization effort
$29 M six-month DTC advertising campaign – Purdue contribution $19M; Transcept contribution $10M – Television ads to commence January 2013 New sales force commitment with 600+ reps – Purdue analgesic sales force of 525 sales representatives will present Intermezzo – Dedicated Intermezzo contract sal
Slide 14: Intermezzo: intellectual property
Intermezzo: intellectual property Intermezzo: intellectual property
Slide 15: Four Intermezzo U.S. patents issued
Four Intermezzo U.S. patents issued Four Intermezzo U.S. patents issued Methods for Treating Middle of- the Night Insomnia 8,242,131 Compositions for Delivering Hypnotic Agents across the Oral Mucosa and Methods of Use thereof 7,682,628 - - U.S. patent title Patent no. Expiration Compositions for Tr
Slide 16: Financial overview
Financial overview Financial overview
Slide 17: Financial position
Financial position (1) Financial position (1) December 31, 2012 Cash, equivalents & investments: ~$85 M (2) Shares outstanding 19 M Options / warrants / other: 3 M Total: 22 M Employees: (3) (1) All numbers are unaudited. (2) Net of $10M Intermezzo DTC investment. (3) On Jan 4, 2013, Transcept annou
Slide 18: Key investment highlights
Intermezzo launched April 2012 – First approval for middle of the night awakening – Large potential market – Significant royalty and co-promote opportunities – 600+ sales reps – DTC launch Jan 2013 Strong balance sheet Key investment highlights Key investment highlights
Slide 19: Trademarks
Intermezzo ® is a registered trademark of Purdue Pharmaceuticals L.P. Ambien ® and Ambien CR ® are registered trademarks of sanofi-aventis Lunesta ® is a registered trademark of Sunovion Pharmaceuticals Inc.
Transcept Pharmaceuticals — Investor Presentation (January 2013) on 6ix